文献速递外周动脉疾病

小隐静脉:自体远端静脉旁路中被低估的来源

The Small Saphenous Vein: An Underestimated Source for Autologous Distal Vein Bypass.
PubMed 文献 · Eur J Vasc Endovasc Surg · 2019-02-26

结果显示1、3、5年一期通畅率分别为68%、58%、54%,二期通畅率1年83%、3年和5年77%,1年保肢率88%、5年78%,1年生存率96%、5年91%。多变量分析确定再次手术为独立危险因素,初次旁路组在通畅率和保肢率上均显著优于再次旁路组。

要点

  • 小隐静脉是外周旁路手术中有价值的替代静脉移植物,尤其适用于大隐静脉或手臂静脉不可用时。
  • 初次旁路患者的小隐静脉移植长期结果优良,再次旁路患者结果也可接受但显著较差。
  • 再次手术是影响小隐静脉旁路通畅率和保肢率的独立危险因素。

核心结论

  • 小隐静脉是外周旁路手术中有价值的替代静脉移植物,长期结果优良,尤其在初次手术患者中,再次手术患者结果也可接受。

主要发现

  • 1年二期通畅率为83%(76-89%),3年和5年均为77%(69-85%)。
  • 1年保肢率为88%(82-94%),5年为78%(70-86%)。
  • 1年生存率为96%(92-99%),5年为91%(85-97%)。

临床怎么用

  • 当大隐静脉或手臂静脉不可用时,可考虑将小隐静脉作为外周旁路的自体静脉移植物。
  • 对于初次旁路患者,小隐静脉移植可获得优良的长期通畅率和保肢率;再次旁路患者结果较差但仍可接受。

局限性

  • 本研究为单中心回顾性数据分析,可能存在选择偏倚和回顾性研究的固有局限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The small saphenous vein (SSV) is a potential vein source for bypass if neither greater saphenous vein nor arm vein is available. This study reports experience using SSV as part of an all autologous vein bypass policy. METHODS: This study comprised single centre retrospective data analysis of all consecutive patients treated at an academic tertiary referral centre from January 1998 to February 2017 using the SSV as the main peripheral bypass graft. Study endpoints were primary patency, secondary patency, limb salvage, and survival. RESULTS: One hundred and twenty operations were performed in 118 patients using SSV. Indications were peripheral arterial occlusive disease (n = 91; Rutherford classification 3: n = 11; 4: n = 21; 5,6: n = 59), acute ischaemia (n = 14), popliteal artery aneurysm (n = 12), and bypass revisions (n = 3). Median follow up was 30.5 months (10 months-13.7 years). Primary patency after one, three and five years was 68% (CI: 59-77%), 58% (49-68%), and 54% (45-64%). Secondary patency was 83% (76-89%) after one year and 77% (69-85%) after three and five years. Limb salvage after one year was 88% (82-94%) and 78% (70-86%) after five years. Survival was 96% (92-99%) after one year and 91% (85-97%) at five years. Multivariable analysis identified redo surgery as an independent risk factor. Patients receiving a primary (n = 59) vs. a redo bypass (n = 61) were compared. Primary patency and secondary patency were both significantly better in the primary bypass group than in the redo group (p = .0036 and p = .0003, respectively). Limb salvage was also significantly better in primary bypass patients than in the redo group (p = .0007), whereas overall survival did not differ significantly (p = .48). CONCLUSION: The SSV is a valuable alternative vein graft in peripheral bypass surgery. It achieves excellent long-term results, particularly in patients with primary procedures but also acceptable results in patients with redo surgery.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Nierlich P, Metzger P, Enzmann FK, et al. The Small Saphenous Vein: An Underestimated Source for Autologous Distal Vein Bypass. Eur J Vasc Endovasc Surg. 2019. PMID: 30824403. doi:10.1016/j.ejvs.2019.01.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。